A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer

Completed · Phase 3

Conditions studied: Breast Cancer

In brief

This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer. Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either 1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.

Key facts

Study ID

NCT00089479

Run by

Hoffmann-La Roche

People needed

2611

Starts

2002-08-01

Expected to finish

2012-05-01

Last updated by the study team

2012-12-21

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• female patients 18-70 years of age;
• adenocarcinoma of the breast;
• previous invasive breast cancer if diagnosed >5 years before entering study;
• no evidence of metastatic disease.

You may not qualify if…

• history of severe hypersensitivity reaction to Taxotere;
• previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;
• treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.

Where it is running

• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.